Drug class
Antiplatelet and vasodilator; phosphodiesterase inhibitor and adenosine uptake inhibitor
Mechanism of action
Inhibits platelet phosphodiesterases and cellular adenosine uptake, increasing intraplatelet cAMP and extracellular adenosine, thereby reducing platelet aggregation and producing vasodilatory effects.
General use cases
- Prevention of thromboembolic complications after prosthetic heart valve replacement in combination with an oral anticoagulant under the product-specific indication
- In combination with aspirin as extended-release dipyridamole for secondary stroke prevention in selected patients with prior ischaemic stroke or transient ischaemic attack; intravenous dipyridamole has a separate myocardial perfusion imaging indication
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
